The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Choosing between ide-cel and cilta-cel for the treatment of R/R multiple myeloma
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the roles of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in treating multiple myeloma (MM). Following positive results from the KarMMa-2 (NCT03601078) and CARTITUDE-4 (NCT04181827) trials, these agents received FDA approval for relapsed/refractory (R/R) MM. Dr Usmani believes cilta-cel is preferable for younger patients, while ide-cel is better suited for older patients, particularly if there are concerns about neurological toxicities. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda.
Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
Speaker: Amgen, BMS, Janssen, Sanofi.
